酮史压 四川龙一医药有限公司 2023 年度－2024 年度审计报告 中国杭州市钱江新城新业路8号UDC时代大厦A座5-8层、12层、23层 FloorsS-8, 12and23,Block A,UDC Times Building,No.8 Xinye Road, Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 中国杭州市钱江新城新业路 8 号 UDC 时代大厦 A 座 5-8 层、12 层、23 层 Floors5-8,12and23,Block A,UDC Times Building,No.8 Xinye Road，Qianjiang New City,Hangzhou Tel.0571-88879999 Fax.0571-88879000 www.zhcpa.cn 审计 报告 中汇会审[2025]8042号 此码用于证明该审计报告是否由具有执业许可的会计师事务所出具， 您可使用手机 "扫一扫 " 或进入 "注册会计师行业统一监管平台 (http://acc.mof即v.cn) " 进行查验。 －． 报告编码：浙25GH1 ...

证券代码：600513 证券简称：联环药业 公告编号：2025-032 江苏联环药业股份有限公司 关于全资子公司对外投资的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）全资子 公司扬州联环投资有限公司（以下简称"联环投资"）拟以自有资金 7,038.00 万元人民币收购成都市川通发企业管理有限公司（以下简称"川通发"）、阳雨 宪、龙小兰所持有的四川龙一医药有限公司（以下简称"龙一医药"）51%股权。 本次收购完成后，龙一医药成为联环投资控股子公司，纳入联环投资合并报表范 围。 ●联环投资与川通发、阳雨宪、龙小兰不存在关联关系，本次股权投资不构 成关联交易，亦不构成《上市公司重大资产重组管理办法》规定的重大资产重组， 本次交易已经公司第九届董事会第十次临时会议审议通过，无需提交股东会审 议。 ●本次交易存在交割先决条件，最终能否成功交割并实施存在不确定性。公 司将根据本次交易的进展情况按规定及时履行信息披露义务，敬请广大投资者注 意投资风险。 一 ...

联环药业（600513）公告，全资子公司扬州联环投资有限公司拟以自有资金7038万元人民币收购成都市 川通发企业管理有限公司、阳雨宪、龙小兰所持有的四川龙一医药有限公司51%股权。本次收购完成 后，龙一医药将成为联环投资的控股子公司，纳入联环投资合并报表范围。联环投资与川通发、阳雨 宪、龙小兰不存在关联关系，本次股权投资不构成关联交易，亦不构成《上市公司重大资产重组管理办 法》规定的重大资产重组。本次交易已经公司第九届董事会第十次临时会议审议通过，无需提交股东会 审议。 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. plans to increase the registered capital of its wholly-owned subsidiary, Yangzhou Lianhuan Investment Co., Ltd., by 60 million RMB to enhance its core competitiveness and optimize its overall industrial layout [2][3]. Group 1: Capital Increase Overview - The capital increase will raise Yangzhou Lianhuan Investment's registered capital from 65 million RMB to 125 million RMB [3]. - The funding for this capital increase will come from the company's self-raised funds [2]. - The subsidiary currently has four holdings and investments across key sectors including pharmaceutical distribution, research and development, overseas investment, and new energy [3]. Group 2: Board Approval and Compliance - The board of directors approved the capital increase at the ninth temporary meeting held on May 26, 2025, and it does not require shareholder approval [4]. - The capital increase does not constitute a related party transaction or a major asset restructuring as defined by relevant regulations [5]. Group 3: Impact of Capital Increase - The capital increase will significantly enhance the financial strength of Yangzhou Lianhuan Investment, providing solid funding support for its investment projects [7]. - This move is expected to strengthen the company's risk resistance capabilities and optimize its revenue structure, aligning with the overall strategic planning of the company [7].

Group 1 - Company Sun Energy plans to repurchase shares worth between 100 million to 200 million yuan for cancellation, with a maximum repurchase price of 6.69 yuan per share [1] - Company Runyang Technology intends to invest up to 300 million yuan in Shanghai Fourier Intelligent Technology Co., with a pre-investment valuation of 8 billion yuan [1] - Company Heng Rui Medicine's subsidiary has received approval for clinical trials of SHR-4712 injection for treating advanced solid tumors [2] Group 2 - Company Lianhuan Pharmaceutical plans to increase capital by 60 million yuan for its wholly-owned subsidiary [2] - Company Hongchang Electronics' subsidiary plans to increase capital by 10 million USD for its other subsidiary [2] - Company Sichuan Meifeng intends to repurchase shares worth between 50 million to 70 million yuan for cancellation, with a maximum repurchase price of 10.07 yuan per share [2] Group 3 - Company Lian Micro plans to liquidate and deregister Jiaxing Kangjing Semiconductor Industry Investment Partnership [4] - Company Jiutian Pharmaceutical has received approval for clinical trials of PDX-04 drug for treating acute gout attacks [5] - Company Pingzhi Information has signed a framework agreement with China Telecom for a GPU computing power project worth approximately 246 million yuan [7] Group 4 - Company Jiu Zhi Tang's subsidiary has initiated Phase II clinical trials for new drug YB211 aimed at treating acute bacterial skin infections [8] - Company Fosun Pharma's subsidiary has received orphan drug designation for HLX22 for gastric cancer treatment in the EU [9] - Company Jianyou Co. plans to repurchase shares worth between 20 million to 40 million yuan for employee stock ownership plans [11] Group 5 - Company Zhi Zheng Co. announced the resignation of its vice president due to personal reasons [13] - Company He Mai Co. signed a cooperation agreement for household photovoltaic systems worth 1 billion yuan [14] - Company Jinan Intelligent's subsidiary won a project bid for electric vehicle charging stations, expected to positively impact performance [16] Group 6 - Company Gaotie Electric plans to distribute a cash dividend of 0.012 yuan per share [18] - Company Guyue Longshan plans to distribute a cash dividend of 0.08 yuan per share [18] - Company Yongmaotai's shareholders plan to reduce their holdings by up to 2.66% of the company's shares [19] Group 7 - Company Tian Cheng Technology's subsidiary received a land idle fee notice for 2.1658 million yuan due to project delays [20] - Company Guangri Co. appointed a new vice president and board secretary to enhance governance [21] - Company Design General Institute won multiple major projects totaling approximately 390 million yuan [22] Group 8 - Company Fuxie Environmental signed a significant contract worth 244 million yuan for a sewage treatment project [23] - Company Lujiazui announced the resignation of its vice chairman due to job transfer [24] - Company Three Squirrels' H-share issuance application has been accepted by the CSRC [24] Group 9 - Company Kanghong Pharmaceutical's subsidiary received approval for clinical trials of KH617 for glioblastoma treatment [25] - Company Xin Zhu Co. announced a suspension of trading to plan an asset acquisition from its controlling shareholder [26] - Company Jianxin Co. announced plans for share reductions by several directors and senior management [28]

证券代码：600513 证券简称：联环药业 公告编号：2025-031 为优化江苏联环药业股份有限公司（以下简称"公司"或"联环药业"）产 业整体布局以及实现总体战略目标，提升全资子公司核心竞争力，联环药业拟以 自筹资金 6,000 万元人民币增加扬州联环投资有限公司（以下简称"联环投资"） 注册资本，本次增资完成后，联环投资注册资本将从 6,500 万元人民币增至 12,500 万元人民币。 江苏联环药业股份有限公司 关于对全资子公司增资的公告 截至本公告披露日，联环投资控股及参股公司共计四家，涵盖医药流通、医 药研发、海外投资、新能源四大核心业务领域。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 增资标的名称：扬州联环投资有限公司 资金来源及增资金额：以自筹资金增资 6,000 万元人民币。 本次增资不涉及关联交易，亦不构成《上市公司重大资产重组管理办法》 规定的重大资产重组情形，无需提交公司股东会审议。 一、增资情况概述 （一）本次增资的基本情况 （一）基本情况 二、增资标的基本情况 公司名称：扬州联 ...

Core Viewpoint - Jiangsu Lianhuan Pharmaceutical Co., Ltd. held its 2024 annual performance briefing on May 21, 2025, to discuss financial status, development strategy, and corporate governance with investors [1] Group 1: Industry Performance - In 2024, the pharmaceutical manufacturing industry achieved a total revenue of 25,298.5 billion yuan, with a year-on-year change of 0.0% [2] - The industry's total operating costs were 14,729.6 billion yuan, reflecting a year-on-year increase of 2.0% [2] - The total profit for the industry was 3,420.7 billion yuan, showing a year-on-year decline of 1.1% [2] Group 2: Company Financials - The company reported an annual revenue of 2.16 billion yuan, with an operating profit of 131 million yuan and a net profit attributable to shareholders of 84 million yuan [2] - In Q1 2025, the net profit attributable to shareholders was approximately 23.06 million yuan [2] Group 3: Reasons for Profit Decline - The decline in net profit for 2024 was primarily due to a significant increase in R&D investment, reduced investment income, and rising operating expenses influenced by changes in medical insurance policies and market demand [2][4] Group 4: Future Growth Points - The company plans to enhance new drug research and technological innovation, with R&D investment reaching 277 million yuan in 2024, a year-on-year increase of 95.93% [2] - The company has made breakthroughs in innovative R&D, including the advancement of a new drug LH-1801 into phase III clinical trials and the approval of multiple generic drug production licenses [2][4] Group 5: Market and Investor Relations - The company emphasizes value management and investor relations, maintaining a consistent annual dividend payout ratio of 30% [5] - The company is committed to improving its image and enhancing communication with investors through various initiatives [5] Group 6: Regulatory Issues - The company is addressing a recent antitrust penalty by implementing corrective measures and has submitted an application for an administrative penalty hearing [4][5]

公司于 2025 年 4 月 18 日在《上海证券报》和上海证券交易所网站披露了《公 司 2024 年年度报告》，并于 2025 年 5 月 14 日披露了《公司关于召开 2024 年度 业绩说明会的公告》（2025-029）。2025 年 5 月 21 日 11:00-12:00，公司董事 长、董事会秘书：钱振华先生、总经理牛犇先生、财务总监薛昊先生、独立董事 张斌先生、证券事务代表葛楷先生共同出席了 2024 年度业绩说明会，针对公司 财务状况、发展战略、公司治理等方面与投资者互动交流和沟通，在信息披露允 许的范围内就投资者关注的问题进行了回答。 二、投资者提出的问题及公司回复情况 证券代码：600513 证券简称：联环药业 公告编号：2025-030 江苏联环药业股份有限公司 关于 2024 年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏联环药业股份有限公司（以下简称"公司"）于 2025 年 5 月 21 日 11:00 — 12:00 ， 通 过 上 海 证 券 交 易 所 上 证 ...

Core Viewpoint - Three pharmaceutical companies, Xianju Pharmaceutical, Tianjin Pharmaceutical, and Lianhuan Pharmaceutical, have been penalized for monopolistic practices related to the raw material dexamethasone sodium phosphate, with total fines amounting to approximately 325 million yuan [1][2][3]. Group 1: Penalties and Financial Impact - Xianju Pharmaceutical was fined a total of approximately 195 million yuan, which includes the confiscation of illegal gains of 23.74 million yuan and a fine of about 172 million yuan based on 8% of its 2023 sales [2][5]. - Tianjin Pharmaceutical faced penalties totaling approximately 69.19 million yuan, including the confiscation of illegal gains of 42.76 million yuan and a reduced fine of about 13.2 million yuan after an 80% reduction [3][5]. - Lianhuan Pharmaceutical was fined approximately 61.04 million yuan, which includes the confiscation of illegal gains of 17.89 million yuan and a reduced fine of about 61.63 million yuan after a 30% reduction [3][5]. Group 2: Profitability Impact - The fines significantly impact the profitability of the companies, with Tianjin Pharmaceutical's penalties representing 2.15% of its recent audited revenue and 51.85% of its net profit attributable to shareholders [5]. - For Xianju Pharmaceutical, the total fine of 195 million yuan accounts for 4.87% of its projected 2024 revenue of 4 billion yuan and 49.17% of its net profit of 397 million yuan [5]. - Lianhuan Pharmaceutical's proposed fines represent 72.53% of its net profit of 84 million yuan for the previous year [5]. Group 3: Recurrence of Violations - Tianjin Pharmaceutical has been penalized for monopolistic behavior for the fourth time in four years, with cumulative fines exceeding 170 million yuan [6][7].

Core Viewpoint - Four companies engaged in a price-fixing conspiracy for dexamethasone phosphate raw materials, leading to significant price increases and resulting in administrative penalties exceeding 350 million yuan [1][5][15] Group 1: Companies Involved - The companies involved in the price-fixing conspiracy are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Xianju Pharmaceutical Co., Ltd. (仙琚制药), Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (西安国康瑞金) [1][5][14] - The main organizer of the conspiracy was identified as an individual named Guo, who facilitated communication and coordination among the companies [5][6] Group 2: Price Changes - The price of dexamethasone phosphate raw materials increased from several thousand yuan per kilogram to over ten thousand yuan, with some companies raising prices as high as 38,000 yuan per kilogram [1][10][14] - Specific price increases included Tianjin Pharmaceutical raising prices from a maximum of 9,000 yuan to 13,800 yuan per kilogram, and Xi'an Guokang Ruijin increasing prices from 7,900 yuan to between 10,000 and 38,000 yuan per kilogram [10][14] Group 3: Administrative Penalties - The total penalties imposed on the companies amounted to over 350 million yuan, with Tianjin Pharmaceutical fined 69.19 million yuan, Xianju Pharmaceutical fined 195.3 million yuan, and Xi'an Guokang Ruijin fined 28.78 million yuan [1][12][13] - Lianhuan Pharmaceutical is expected to face a fine of 61.04 million yuan, with a proposed reduction of 30% due to its cooperation during the investigation [1][11] Group 4: Cooperation and Leniency - Tianjin Pharmaceutical was the first to submit a leniency application, providing crucial evidence and reporting the details of the price-fixing agreement, which led to an 80% reduction in its fine [2][11] - In contrast, Xianju Pharmaceutical and Xi'an Guokang Ruijin did not submit leniency applications, resulting in no reductions in their fines [2][12][14]